Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-26T06:10:25.841Z Has data issue: false hasContentIssue false

Chapter 24 - Secondary Prevention

from Section 4 - Therapeutic Strategies and Neurorehabilitation

Published online by Cambridge University Press:  16 May 2019

By
Hans-Christoph Diener  and
Gregory W. Albers
Edited by
Michael Brainin  and
Wolf-Dieter Heiss
Michael Brainin
Affiliation:
Donau-Universität Krems, Austria
Wolf-Dieter Heiss
Affiliation:
Universität zu Köln
Get access
Type
Chapter
Information
Textbook of Stroke Medicine , pp. 410 - 425
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Grau, AJ, Weimar, C, Buggle, F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001; 32(11): 2559–66.Google Scholar
Amarenco, P, Lavallee, PC, Labreuche, J, et al. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 2016; 374(16): 1533–42.Google Scholar
Lovett, JK, Coull, AJ, Rothwell, PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62(4): 569–73.CrossRefGoogle ScholarPubMed
Knoflach, M, Lang, W, Seyfang, L, et al. Predictive value of ABCD2 and ABCD3-I scores in TIA and minor stroke in the stroke unit setting. Neurology 2016; 87(9): 861–9.CrossRefGoogle ScholarPubMed
Rothwell, PM, Giles, MF, Chandratheva, A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370(9596): 1432–42.Google Scholar
Yusuf, S, Teo, KK, Pogue, J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547–59.Google ScholarPubMed
Rashid, P, Leonardi-Bee, J, Bath, P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 2003; 34(11): 2741–9.Google Scholar
Katsanos, AH, Filippatou, A, Manios, E, et al. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension 2017; 69(1): 171–9.Google Scholar
Flather, MD, Yusuf, S, Kober, L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355(9215): 1575–81.Google Scholar
Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033–41.Google Scholar
Schrader, J, Luders, S, Kulschewski, A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36(6): 1218–26.Google Scholar
Yusuf, S, Diener, HC, Sacco, RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359(12): 1225–37.CrossRefGoogle ScholarPubMed
Elkind, MS, Luna, JM, McClure, LA, et al. C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study. Stroke 2014; 45(3): 707–16.Google Scholar
Amarenco, P, Labreuche, J, Lavallee, P, Touboul, PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35(12): 2902–9.CrossRefGoogle ScholarPubMed
Jellinger, PS, Handelsman, Y, Rosenblit, PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice 2017; 23(2): 1–87.CrossRefGoogle Scholar
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7–22.CrossRefGoogle Scholar
Collins, R, Armitage, J, Parish, S, Sleight, P, Peto, R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363(9411): 757–67.Google ScholarPubMed
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355(6): 549–59.Google Scholar
Milionis, H, Barkas, F, Ntaios, G, et al. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: effect on stroke risk. Eur J Intern Med 2016; 34: 54–7.Google Scholar
Blanco, M, Nombela, F, Castellanos, M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69(9): 904–10.Google Scholar
Ray, KK, Seshasai, SR, Wijesuriya, S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373(9677): 1765–72.Google Scholar
Lee, M, Saver, JL, Liao, HW, Lin, CH, Ovbiagele, B. Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke 2017; 48(2): 388–93.Google Scholar
Zinman, B, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke 2017; 48(5): 1218–25.Google ScholarPubMed
Toole, JF, Malinow, MR, Chambless, LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291(5): 565–75.Google Scholar
Lonn, E, Yusuf, S, Arnold, MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354(15): 1567–77.Google Scholar
Spence, JD, Yi, Q, Hankey, GJ. B vitamins in stroke prevention: time to reconsider. Lancet Neurol 2017; 16(9): 750–60.Google Scholar
Viscoli, CM, Brass, LM, Kernan, WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345(17): 1243–9.Google Scholar
Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308(6921): 81–106.Google Scholar
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71–86.CrossRefGoogle Scholar
Born, G, Patrono, C. Antiplatelet drugs. Br J Pharmacol 2006; 147(Suppl 1): S241–51.Google Scholar
Algra, A, van Gijn, J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 65(2): 255.Google Scholar
Rothwell, PM, Algra, A, Chen, Z, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388(10042): 365–75.Google Scholar
Patrono, C, Garcia Rodriguez, LA, Landolfi, R, Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353(22): 2373–83.Google Scholar
Topol, E, Easton, D, Harrington, R, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108(4): 399–406.Google Scholar
Yusuf, S, Zhao, F, Mehta, SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494–502.Google Scholar
Li, L, Geraghty, OC, Mehta, Z, Rothwell, PM, Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017; 390(10093): 490–9.Google Scholar
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329–39.Google Scholar
Diener, H, Bogousslavsky, J, Brass, L, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364(9431): 331–7.Google Scholar
Bhatt, DL, Fox, KA, Hacke, W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16): 1706–17.Google Scholar
Bhatt, DL, Flather, MD, Hacke, W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49(19): 1982–8.Google Scholar
Diener, HC, Cuhna, L, Forbes, C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicyclic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143(1–2): 1–13.CrossRefGoogle Scholar
Diener, HC, Darius, H, Bertrand-Hardy, JM, Humphreys, M. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001; 55(3): 162–3.Google Scholar
The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367(9523): 1665–73.Google Scholar
Diener, HC, Sacco, R, Yusuf, S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007; 23(5–6): 368–80.Google Scholar
Johnston, SC, Amarenco, P, Albers, GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016; 375(1): 35–43.Google Scholar
Hankey, GJ. Stroke. Lancet 2017; 389(10069): 641–54.Google Scholar
Benavente, OR, Hart, RG, McClure, LA, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367(9): 817–25.Google Scholar
Wang, Y, Wang, Y, Zhao, X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369(1): 11–19.CrossRefGoogle ScholarPubMed
Kirchhof, P, Benussi, S, Kotecha, D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893–962.CrossRefGoogle ScholarPubMed
EAFT Trial Investigators. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342(8882): 1255–62.Google Scholar
Saxena, R, Koudstaal, PJ. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004; 4: CD000187.Google Scholar
Hart, R, Pearce, L, Miller, V, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000; 10(1): 39–43.Google Scholar
Hylek, EM, Evans-Molina, C, Shea, C, Henault, LE, Regan, S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115(21): 2689–96.CrossRefGoogle ScholarPubMed
Connolly, S, Pogue, J, Hart, R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367(9526): 1903–12.Google Scholar
Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139–51.CrossRefGoogle ScholarPubMed
Patel, MR, Mahaffey, KW, Garg, J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883–91.Google Scholar
Granger, CB, Alexander, JH, McMurray, JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981–92.Google Scholar
Connolly, SJ, Eikelboom, J, Joyner, C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364(9): 806–17.CrossRefGoogle ScholarPubMed
Giugliano, RP, Ruff, CT, Braunwald, E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093–104.Google Scholar
Ntaios, G, Papavasileiou, V, Diener, HC, Makaritsis, K, Michel, P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2017; 12(6): 589–96.CrossRefGoogle ScholarPubMed
Homma, S, Thompson, JL, Pullicino, PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366(20): 1859–69.Google Scholar
Paciaroni, M, Agnelli, G, Caso, V, et al. Prediction of early recurrent thromboembolic event and major bleeding in patients with acute stroke and atrial fibrillation by a risk stratification schema: the ALESSA Score Study. Stroke 2017; 48(3): 726–32.Google Scholar
Paciaroni, M, Agnelli, G, Ageno, W, Caso, V. Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost 2016; 116(3): 410–16.Google Scholar
Arihiro, S, Todo, K, Koga, M, et al. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke 2016; 11(5): 565–74.Google Scholar
Hagen, PT, Scholz, DG, Edwards, WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59(1): 17–20.Google Scholar
Furlan, AJ, Reisman, M, Massaro, J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366(11): 991–9.Google Scholar
Carroll, JD, Saver, JL, Thaler, DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368(12): 1092–100.Google Scholar
Meier, B, Kalesan, B, Mattle, HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368(12): 1083–91.Google Scholar
Mas, JL, Derumeaux, G, Guillon, B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017; 377(11): 1011–21.CrossRefGoogle ScholarPubMed
Sondergaard, L, Kasner, SE, Rhodes, JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377(11): 1033–42.Google Scholar
Saver, JL, Carroll, JD, Thaler, DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377(11): 1022–32.CrossRefGoogle ScholarPubMed
The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42(6): 857–65.Google Scholar
Mohr, JP, Thompson, JL, Lazar, RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–51.CrossRefGoogle ScholarPubMed
The ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6(2): 115–24.Google Scholar
Algra, A, De Schryver, EL, van Gijn, J, Kappelle, LJ, Koudstaal, PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006; 3: CD001342.Google Scholar
Levine, SR, Brey, RL, Tilley, BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291(5): 576–84.Google Scholar
CADISS Trial Investigators, Markus, HS, Hayter, E, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol 2015; 14(4): 361–7.Google Scholar
Lyrer, P, Engelter, S. Antithrombotic drugs for carotid artery dissection. Stroke 2004; 35(2): 613–14.CrossRefGoogle ScholarPubMed
Caprio, FZ, Bernstein, RA, Alberts, MJ, et al. Efficacy and safety of novel oral anticoagulants in patients with cervical artery dissections. Cerebrovasc Dis 2014; 38(4): 24–53.Google Scholar
Barnett, HJ, Taylor, DW, Eliasziw, M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998; 339(20): 1415–25.Google Scholar
European Carotid Surgery Trialists' Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351(9113): 1379–87.Google Scholar
European Carotid Surgery Trialists' Collaborative Group. MRC European carotid surgery trial: interim results for symptomatic patients with severe carotid stenosis and with mild carotid stenosis. Lancet 1991; 337(8752): 1235–43.Google Scholar
Ferguson, GG, Eliasziw, M, Barr, HWK, et al. The North American symptomatic carotid endarterectomy trial: surgical result in 1 415 patients. Stroke 1999; 30(9): 1751–8.Google Scholar
Rothwell, PM, Warlow, CP, on behalf of the European Carotid Surgery Trialists’ Collaborative Group. Prediction on benefit from carotid endarterectomy in individual patients: a risk-modelling study. Lancet 1999; 353(9170): 2105–10.Google Scholar
Rothwell, PM, Eliasziw, M, Gutnikov, SA, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361(9352): 107–16.Google Scholar
Rothwell, P, Eliasziw, M, Gutnikov, S, Warlow, C, Barnett, H, Carotid Endarterectomy Trialists’ Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363(9413): 915–24.Google Scholar
Chaturvedi, S, Bruno, A, Feasby, T, et al. Carotid endarterectomy – an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65(6): 794–801.CrossRefGoogle Scholar
Ringleb, PA, Allenberg, J, Bruckmann, H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006; 368(9543): 1239–47.Google Scholar
Stingele, R, Berger, J, Alfke, K, et al. Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol 2008; 7(3): 216–22.Google Scholar
Mas, JL, Chatellier, G, Beyssen, B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355(16): 1660–71.Google Scholar
Brott, TG, Hobson, RW, 2nd, Howard, G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363(1): 11–23.Google Scholar
Markus, HS, Larsson, SC, Kuker, W, et al. Stenting for symptomatic vertebral artery stenosis: the Vertebral Artery Ischaemia Stenting Trial. Neurology 2017; 89(12): 1229–36.Google Scholar
Bonati, LH, Lyrer, P, Ederle, J, Featherstone, R, Brown, MM. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 2012; 9: CD000515.Google Scholar
Chimowitz, MI, Lynn, MJ, Howlett-Smith, H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352(13): 1305–16.Google Scholar
Kasner, SE, Chimowitz, MI, Lynn, MJ, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006; 113(4): 555–63.Google Scholar
Chimowitz, MI, Lynn, MJ, Derdeyn, CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365(11): 993–1003.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×